Search

Your search keyword '"Lanreotide -- Forecasts and trends"' showing total 4 results
Start Over Descriptor "Lanreotide -- Forecasts and trends" Topic mycapssa (medication)
4 results on '"Lanreotide -- Forecasts and trends"'

1. COMP Adopts Positive Opinion on Orphan Designation for Mycapssa(R) for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors

Subjects
Tumors -- Care and treatment, Lanreotide -- Forecasts and trends, Orphan drugs -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Business, European Union, European Union. European Commission, Mycapssa (Medication)
Abstract

COMP Adopts Positive Opinion on Orphan Designation for Mycapssa(R) for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors DUBLIN, Ireland, and Boston MA, December 19, 2022 Amryt (Nasdaq: AMYT), [...]

Published
2022

2. European Commission approves Mycapssa(R) for the treatment of Acromegaly

Subjects
Lanreotide -- Forecasts and trends, Drug approval -- Forecasts and trends, Acromegaly -- Care and treatment, Market trend/market analysis, Banking, finance and accounting industries, Business, European Union, European Union. European Commission, Mycapssa (Medication)
Abstract

European Commission approves Mycapssa(R) for the treatment of Acromegaly Mycapssa(R) will be the first and only oral somatostatin analog approved in the EU Approval based on MPOWERED Phase 3 trial [...]

Published
2022

3. COMP adopts positive opinion on Orphan Disease Designation for Mycapssa(R) for the treatment of Acromegaly

Subjects
Lanreotide -- Forecasts and trends, Orphan drugs -- Forecasts and trends, Acromegaly -- Care and treatment, Market trend/market analysis, Banking, finance and accounting industries, Business, European Union, Mycapssa (Medication)
Abstract

COMP adopts positive opinion on Orphan Disease Designation for Mycapssa(R) for the treatment of Acromegaly DUBLIN, Ireland, and Boston MA, October 18, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical [...]

Published
2022

4. Amryt Announces Successful Bioavailability Study for MycapssaA (octreotide capsules)

Subjects
United States. Food and Drug Administration, Lanreotide -- Forecasts and trends, Market trend/market analysis, Banking, finance and accounting industries, Mycapssa (Medication)
Abstract

(GlobeNewswire) - Amryt Announces Successful Bioavailability Study for Mycapssa (octreotide capsules) Data supports a planned Phase 3 study in the treatment of carcinoid symptoms associated with Neuroendocrine Tumors (NET) Global [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results